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The present investigation was aimed to study the antidiabetic, antihyperlipidemic, and in vivo antioxidant properties of the root
of Sphaeranthus indicus Linn. in streptozotocin- (STZ-) induced type 1 diabetic rats. Administration of ethanolic extract of
Sphaeranthus indicus root (EESIR) 100 and 200mg/kg to the STZ-induced diabetic rats showed signiﬁcant (P<. 01) reduction
in blood glucose and increase in body weight compared to diabetic control rats. Both the doses of EESIR-treated diabetic rats
showed signiﬁcant (P<. 01) alteration in elevated lipid proﬁle levels than diabetic control rats. The EESIR treatment in diabetic
rats produced signiﬁcant increase in superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and decrease in
thiobarbituric acid reactive substances (TBARS) levels than diabetic control rats. Administration of EESIR 200mg/kg produced
signiﬁcant (P<. 01) higher antioxidant activity than EESIR 100mg/kg. The high performance liquid chromatography (HPLC)
analysis of EESIR revealed the presence of biomarkers gallic acid and quercetin. In conclusion, EESIR possess antidiabetic,
antihyperlipidemic, and in vivo antioxidant activity in type 1 diabetic rats. Its antioxidant and lipid lowering eﬀect will help to
prevent diabetic complications, and these actions are possibly due to presence of above biomarkers.
1.Introduction
Diabetes mellitus (DM) is a group of metabolic diseases
characterized by hyperglycemia resulting from the defects
in insulin secretion, insulin action, or both. A chronic
hyperglycemic condition in diabetes is associated with long-
term damage, dysfunction, and failure of various organs,
such as eyes, kidneys, nerves, heart, and blood vessels. It
is the most common serious metabolic disorder and is
considered to be one of the ﬁve leading causes of death in
the world [1]. DM is classiﬁed into two major categories:
type 1 and type 2 diabetes. Although both types of diabetes
have distinct pathogenesis, hyperglycemia, and various life-
threatening complications are common to both [2]. The
plasma lipids are usually raised in diabetes and such an
elevation represents a risk factor for coronary heart disease
[3]. Free radicals have signiﬁcant role in the causation of
several diseases like diabetes, parkinson’s disease, cirrhohsis,
cancer, and cardiovascular disorders [4]. In DM, oxidative
damage and tissue injury may lead to alterations in the
endogenous free radical scavenging defense mechanisms and
ineﬀective scavenging of reactive oxygen species [5]. The
current treatment for control of DM includes diet, exercise,
oralantidiabeticdrugs,andinsulintherapy.However,insulin
andotheroralhypoglycemicdrugshavecharacteristicproﬁle
of adverse eﬀects. This has initiated the identiﬁcation of
novel drugs which might act in mechanistically distinct
way compared to existing drug targets [6]. Hence, research2 Evidence-Based Complementary and Alternative Medicine
is focused on medicinal plants which are used in the
traditional practices and development of newer drug leads
from phytoconstituents with more potential and eﬀective
agents with lesser side eﬀects than the existing hypoglycemic
agents[1].Traditionally,manymedicinalplantsarecurrently
usedin India forthetreatmentof diabetes and its eﬃcacyhas
been proved scientiﬁcally [7].
Sphaeranthus indicus Linn. (Family-Compositae) is a
branched herb with purple ﬂowers that grows abundantly in
rice ﬁeld and distributed throughout India. It is used indige-
nously in the Indian system of medicine as an anthelmintic
[8]. The plant has a wide range of medicinal value and
has been used in hemicranias, jaundice, leprosy, diabetes,
fever, pectoralgia, cough, gastropathy, hernia, hemorrhoids,
helminthiasis, dyspepsia, skin diseases and nerve tonic [9,
10] .P h a r m a c o l o g i c a la c t i v i t i e ss u c ha si m m u n o m o d u l a t o r y
[11], antimicrobial [12, 13], antibacterial [14, 15], anxiolytic
[10], wound healing action [16] were reported on this plant.
Phytoconstituents isolated from this plant are eudesman-
olides [17], isoﬂavonoids [18], 7-hydroxy eudesmanolides
[19], sterol glycoside [20], essential oil (cadiene, ocimene,
citral, p-methoxycinnamaldehyde, geraniol, eugenol and
geranyl acetate) [21], and eudesmanolides [22]. In India, the
tribals of Madhya Pradesh used this plant for the treatment
of diabetes [23]. Globally, type 1 DM aﬀects considerable
percentage of population and it leads to morbidity and
mortality of the diabetic patients. Antioxidants play a major
role in the prevention of diabetes and its complications by
scavenging free radicals. Survey of current literature revealed
that there is no scientiﬁc data documented for the eﬀect of
Sphaeranthus indicus root in the treatment of type 1 diabetes
mellitus and its in vivo antioxidant action. Therefore, the
present study was undertaken to investigate the antidiabetic,
antihyperlipidemic and in vivo antioxidant potential of
EESIR in type 1 diabetic rats as well as identiﬁcation of the
p o s s i b l eb i o m a r k e r si nE E S I R .
2. Methods
2.1. Plant Material. Sphaeranthus indicus Linn. was col-
lected from Erode, Tamil Nadu, India and authenticated by
Dr.P.Venu, Joint Director of Botanical Survey of India, Tamil
Nadu Agriculture University (TNAU), Coimbatore. The
authentication certiﬁcate bearing number BSI/SC/5/21/04-
05/Tech-1850 is documented in our laboratory. The roots
were separated, cleaned, air dried under shade and powdered
using mechanical grinder and stored in air-tight container.
2.2. Preparation of EESIR. Dried powdered plant roots
were (85g) extracted with 70% v/v ethanol using Soxhlet
apparatus for 72 hours. The extract was concentrated under
reduced pressure in rota evaporator and yield of the extract
was found to be 15.24g. The EESIR was stored at 10
◦Ci nt h e
refrigerator until the completion of pharmacological studies.
2.3. Drugs and Chemicals. Acetonitrile: n-hexane sulphonic
acid were of HPLC grade (Himedia, Mumbai). Gallic acid
and quercetin reference standards were purchased from
Sigma Aldrich (USA). Streptozotocin was procured from
Sisco Research Laboratories Private Ltd., Mumbai, India. All
other chemicals and reagents were of analytical grade, and
enzymatic kits used in this study were obtained commer-
cially.
2.4. Preparation of Standard and Sample Solutions for HPLC.
Stock solutions of gallic acid (GA) and quercetin (QA) were
prepared at concentration of 1000μg/ml and 2000μg/ml
immediately before use and used as reference standard.
The EESIR was dissolved in mobile phase, to obtain a
concentration of 4mg/ml and used as sample solution. All
sample solutions were ﬁltered through 0.45μmm e m b r a n e
ﬁlter (Millipore) and injected directly.
2.5. Chromatographic Conditions for HPLC. Chromato-
graphic analysis was carried out by Phenomenex-Luna C18
reversed-phase column (ø 250mm × 4.6mm) packed with
5μm diameter particles; the mobile phase was acetonitrile:
n-hexane sulphonic acid (20:80 v/v) pH 2.5 adjusted with
glacial acetic acid. This mobile phase was ﬁltered through
a0 . 4 5 μm membrane ﬁlter (Millipore), then deaerated
ultrasonically prior to use. The GA and QA were quantiﬁed
by photodiode array detector following HPLC separation at
299nm. The mobile phase ﬂow rate and injection volume
were 1.2ml/min and 20μL, respectively. The chromato-
graphic peaks of the analytes were conﬁrmed by comparing
their retention time (Rt) and UV spectra with those of
the reference standards. The GA (2.5 to 12.5μg/ml) and
QA (10 to 80μg/ml) standard solutions were injected into
the HPLC and peak area responses obtained. Standard
graphs were prepared by plotting concentration versus area.
Quantiﬁcation was carried out from integrated peak areas
of the samples using the corresponding standard graph. All
c h r o m a t o g r a p h i co p e r a t i o n sw e r ec a r r i e do u ta ta m b i e n t
temperature.
2.6. Experimental Animals. Wistar albino rats of both sexes
weighing 150−200g were used for the study. All animals
weremaintainedunderstandardlaboratoryconditions[tem-
perature (22 ± 2◦C) and humidity (45 ± 5◦C)] with
1 2h o u r sd a y :1 2h o u r sn i g h tc y c l e .T h ea n i m a l sw e r ef e d
with normal laboratory diet and allowed to drink water
ad libitum. All the experimental procedures conducted after
the approval of ethical committee (817/04/ac/CPCSEA) and
were in strict accordance with institutional animal ethical
committee guidelines for the care and use of laboratory
animals.
2.7. Acute Toxicity. Acute oral toxicity study was performed
as per Organization for Economic Cooperation and Devel-
opment (OECD) guidelines 423 [24]. After the oral adminis-
tration of EESIR, animals were observed individually at least
once during the ﬁrst 30 minutes and periodically during the
ﬁrst 24 hours, with special attention given during the ﬁrst 4
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2.8.InductionofDiabetes. Diabeteswasinducedinovernight
fasted rats by intraperitoneal injection of STZ at a dose of
60mg/kg body weight [25]i n0 . 1Mc o l dc i t r a t eb u ﬀer (pH
4.5).STZcaninducefatalhypoglycemiaasaresultofmassive
pancreatic insulin release and to avoid this hypoglycemic
eﬀect, the rats were provided with 5% dextrose solution after
6 hours of STZ administration for next 24 hours. Induction
of diabetes was veriﬁed after 72 hours and the animals were
allowed 14 days for the stabilization of blood glucose level.
At 14th day, animals having a blood glucose level higher
than 210mg/dl were considered diabetic and used for the
experiments.
2.9. Experimental Design for Antidiabetic Activity. The rats
were divided into ﬁve groups of six each randomly: group
1 normal untreated rats which received 0.2% carboxy methyl
cellulose (CMC) served as normal control, group 2 diabetic
rats received 0.2% CMC served as diabetic control, group 3
diabetic rats received EESIR (100mg/kg), group 4 diabetic
rats received EESIR (200mg/kg), and group 5 diabetic rats
received glibenclamide (5mg/kg). The EESIR and gliben-
clamide was suspended in 0.2% CMC and administered
orally for 28 days once daily to the respective groups. On the
28th day, the animals were fed with respective dose of drug
and, the body weights of all the animals were determined
and blood samples were collected after 1 hour post drug
dose. The serum was separated by centrifugation of blood
at 5000rpm for 10 minutes and the biochemical parameters
were analyzed.
2.10. Estimation of Glucose and Lipid Proﬁle Levels. The
blood glucose level was determined by glucose oxidase-
peroxidase method using glucose enzymatic kit (Agappe
diagnostic, Kerala, India) and expressed in milligrams per
deciliter (mg/dl). The lipid proﬁles such as total cholesterol
(TC), triglycerides (TG), high density lipoprotein (HDL)
were determined using enzymatic kits (Agappe diagnostic,
Kerala, India) and low density lipoprotein (LDL), very
low density lipoprotein (VLDL) values were calculated by
Friedewalds formula as given below [26]
VLDL = TG/5, (1)
LDL = TC −(HDL+VLDL). (2)
2.11.DeterminationofLipidPeroxidationIndicesandAntioxi-
dantLevels. Liverwasdissectedoutandwashedimmediately
with ice cold saline to remove blood. Tissue homogenate
(10% w/v) was prepared with 0.025M Tris−HCl buﬀer (pH
7.5) and was used for the assay of lipid peroxidation [27],
superoxide dismutase [28], catalase [29], and glutathione
peroxidase [30].
2.12. Statistical Analysis. All the data are expressed as mean
± SEM and evaluated by one way analysis of variance
(ANOVA), employing Dunnett’s test for multiple compar-
isons and values of P<. 05 were considered as statistically
signiﬁcant.
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Figure 1: HPLC chromatogram of standard gallic acid and quer-
cetin.
3. Results
3.1. HPLC Estimation. The HPLC ﬁngerprints of the EESIR
showed two types of the phytoconstituents, gallic acid, and
quercetin. The retention time of standard GA and QA
were found to be 2.685 and 6.664 (Figure 1). The retention
time of GA and QA in EESIR was found to be 2.650 and
6.908 (Figure 2), and it matched with standard Rt values,
respectively. The amount of GA and QA in EESIR was found
to be 1.92mg/g and 216mg/g of extract.
3.2. Determination of Acute Toxicity, Body Weight, and
Glucose Levels. The oral administration of EESIR at the dose
2000mg/kg did not exhibit death and any signs of toxicity up
to 14 days (LD50 > 2000mg/kg). Therefore, the biological
evaluation was carried out using 100 and 200mg/kg dose
levels.Thebodyweightofthediabeticratsshowedsigniﬁcant
(P<. 01) reduction after the administration of STZ
compared to normal control rats. The treatment of EESIR
at a dose 100 and 200mg/kg showed a signiﬁcant (P<. 01)
increase in body weight compared to diabetic control rats.
The eﬀect of EESIR at 200mg/kg dose level on body weight
is almost equal to that of glibenclamide (Figure 3). Both the
doses of EESIR showed signiﬁcant (P<. 01) reduction in
elevated blood glucose level compared to diabetic control
group. The administration of EESIR 200mg/kg produced
signiﬁcant (P<. 01) decrease in blood glucose level than
100mg/kg, and however, it was found less eﬀective than the
standard drug glibenclamide in controlling elevated blood
glucose level (Figure 4).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: HPLC chromatogram of EESIR for gallic acid and
quercetin.
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Figure 3:EﬀectofethanolicextractofSphaeranthusindicusroot on
body weight in STZ-induced diabetic rats. All data are expressed in
mean ± SEM (n = 6). aP<. 01: diabetic control group compared
with normal control group. bP<. 01: EESIR 100, 200mg/kg and
glibenclamide 5mg/kg compared with diabetic control group. cP<
.01: EESIR 200mg/kg compared with EESIR 100mg/kg group.
3.3. Alteration of Lipid Proﬁle by EESIR . In this study, after
administration of STZ, profound alterations of the lipid
proﬁle were seen in diabetic rats. Both the doses of EESIR
showed signiﬁcant (P<. 01) reduction in elevated TC,
TG, and LDL levels and increased HDL level. The dose of
200mg/kg showed signiﬁcant (P<. 05 and P<. 01) higher
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Figure 4:EﬀectofethanolicextractofSphaeranthusindicusroot on
blood glucose in STZ-induced diabetic rats. All data are expressed
in mean ± SEM (n = 6). aP<. 01: diabetic control group compared
with normal control group. bP< . 01: EESIR 100, 200mg/kg and
glibenclamide 5mg/kg compared with diabetic control group. cP<
.01: EESIR 200mg/kg compared with EESIR 100mg/kg group.
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Figure 5: Eﬀect of ethanolic extract of Sphaeranthus indicus root
on TC and TG in STZ-induced diabetic rats. All data are expressed
in mean ± SEM (n = 6). aP<. 01: diabetic control compared
with normal control group. bP<. 01: EESIR 100, 200mg/kg and
glibenclamide 5mg/kg compared with diabetic control group. cP<
.05: EESIR 200mg/kg compared with EESIR 100mg/kg group. eP<
.01: EESIR 200mg/kg compared with glibenclamide 5mg/kg group.
fP<. 01: EESIR 200mg/kg compared with EESIR 100mg/kg group.
reductioninelevatedTC,TG,andLDLlevelswhencompared
to glibenclamide and 100mg/kg dose of EESIR. The HDL
level at the dose of EESIR 200mg/kg was signiﬁcantly
increased compared to glibenclamide and EESIR 100mg/kg
(P<. 01). Administration of EESIR and glibenclamide to
diabetic rats showed signiﬁcant (P<. 01) reduction in VLDL
level than diabetic control (Figures 5 and 6).Evidence-Based Complementary and Alternative Medicine 5
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Figure 6: Eﬀect of ethanolic extract of Sphaeranthus indicus root
on HDL, LDL, and VLDL in STZ-induced diabetic rats. All data
are expressed in mean ± SEM (n = 6). aP<. 01: diabetic
control compared with normal control group. bP<. 01: EESIR
100, 200mg/kg and glibenclamide 5mg/kg compared with diabetic
control group. dP<. 05: glibenclamide 5mg/kg compared with
diabetic control group. eP<. 01: EESIR 200mg/kg compared with
glibenclamide 5mg/kg group. fP<. 01: EESIR 200mg/kg compared
with EESIR 100mg/kg group.
3.4. Antioxidant Action in Liver Homogenate. There was a
signiﬁcant reduction of SOD, GPx, and CAT and elevation
o fT B A R Sl e v e l sw e r eo b s e r v e di nd i a b e t i cr a t sc o m p a r e d
to control animals. The administration of EESIR (P<
.01 and P<. 05) signiﬁcantly increased the SOD, GPx,
CAT and reduced TBARS level in dose-dependant manner
(Figures 7 and 8). However, the dose of 200mg/kg dose
of EESIR signiﬁcantly (P<. 01) increased SOD and CAT
level when compared to 100mg/kg dose group. Moreover,
diabetic rats treated with EESIR 200mg/kg showed equal
eﬃcacy to improve antioxidant level compared to standard
drug glibenclamide.
4. Discussion
The administration of STZ produces selective pancreatic
islet beta cell cytotoxicity and has been commonly used to
produce type 1 diabetes in the experimental animal model
[31]. The loss of body weight after administration of STZ
may be due to the loss of degradation of structural proteins
[32]. The administration of EESIR improves body weight
compared to diabetic rats and it indicates preventive eﬀect
of EESIR on degradation of structural proteins. The massive
destruction of pancreatic beta cells after STZ injection is
due to alkylation of DNA thereby producing hyperglycaemia
[33], and it accounts for drastic reduction in insulin level
which in turn alters glucose utilization and metabolism. The
medicinal plants having hypoglycemic activity act through
multiple mechanisms such as improving insulin sensitivity,
augmenting glucose-dependent insulin secretion, and stim-
ulating the regeneration of islets of langerhans in pancreas
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Figure 7:EﬀectofethanolicextractofSphaeranthusindicusroot on
SOD and CAT in STZ-induced diabetic rats. All data are expressed
in mean ± SEM (n = 6). aP<. 01: diabetic control compared
with normal control group. bP<. 01: EESIR 100, 200mg/kg and
glibenclamide 5mg/kg compared with diabetic control group. dP<
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No signiﬁcance.
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Figure 8:EﬀectofethanolicextractofSphaeranthusindicusroot on
GPx and LPO in STZ-induced diabetic rats. All data are expressed
in mean ± SEM (n = 6). aP<. 01: diabetic control compared
with normal control group. bP<. 01: EESIR 100, 200mg/kg and
glibenclamide 5mg/kg compared with diabetic control group. cP<
.05: EESIR 200mg/kg and glibenclamide 5mg/kg compared with
diabetic control group. ns: No signiﬁcance.
of STZ-induced diabetic rats [34]. After the administration
of EESIR, signiﬁcant reduction in elevated glucose level was
observed in diabetic rats, and it may be due to the action
mediated by EESIR in any one of the above mechanism.6 Evidence-Based Complementary and Alternative Medicine
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Figure 9: Schematic diagram.
The risk of coronary heart disease risk (CHD) is
increased in DM due to profound alterations in the plasma
lipids and lipoprotein proﬁle [35, 36]. The elevated level of
total cholesterol is one of the major factors for occurrence
of CHD. Also, altered lipid proﬁle levels and the incidence
of atherosclerosis are increased in DM [37]. Hence, control
or reduction of lipid proﬁles level in diabetic condition
would reduce mortality rate. Many medicinal plants and
herbs reported to possess antihyperlipidemic and antidia-
betic eﬀect [38, 39]. The blood glucose and lipid lowering
eﬃcacy of EESIR could be beneﬁcial in preventing diabetic-
related complications and to improve compliance of diabetic
patients.
Oxidative stress plays a major role in generation of
free radicals in the pathogenesis of diabetes and its com-
plications. In the pathogenesis of diabetic complication,
oxidative processes mediated by free radicals have major
role. Autoxidation of glucose and nonenzymatic protein
glycation occurs during persistent hyperglycemia, and this
may cause disruption of cellular function and oxidative
damage of cell membranes due to increased level of free
radicals. The cell components such as lipid, protein, DNA,
and carbohydrates are aﬀected by free radicals. The lipids
are aﬀected by higher level than protein and carbohydrates
[40]. In present study, oxidative stress induced by STZ may
lead to disturbance of in vivo antioxidant system. The level
of lipid peroxidation (TBARS) and reactive oxygen species
(superoxide anion, hydrogen peroxide, and hydroxyl radical)
are common markers of oxidative stress in diabetic rats. An
increased level of TBARS was observed in diabetic rats and
the administration of EESIR signiﬁcantly reduced TBARS
levels. The SOD catalyses the conversion of superoxide anion
to hydrogen peroxide and oxygen [41]. In diabetic rats, liver
SOD level was reduced on comparison to normal control
and after EESIR treatment there was a signiﬁcant increase
in SOD level. CAT is a hemoprotein enzyme and it catalyzes
the reduction of hydrogen peroxide and protects tissues from
highly reactive hydroxyl radicals [42]. The level of CAT
was reduced in diabetic rats and administration of EESIR
improved CAT level in diabetic rats. In normal condition,
GPx detoxiﬁes hydrogen peroxide to water through the
oxidation of reduced glutathione [43]. The decreased level of
GPx activity in diabetic control rats indicates an important
adaptive response to increased peroxidative stress [44]. The
administration of EESIR showed increased GPx activity
when compared to diabetic control rats. The ability of EESIREvidence-Based Complementary and Alternative Medicine 7
to restore the antioxidant status in diabetic rats clearly
indicates its free radical scavenging property. The present
study provides more scientiﬁc support to the in vitro report
[45].
The HPLC chromatogram conﬁrms the presence of
biomarkers such as gallic acid and quercetin in EESIR. The
insulin releasing capacity of quercetin in isolated rat islets
of langerhans is well documented [46]. The antioxidant
property of gallic acid has been reported [47] and enhance-
ment of insulin receptor sensitivity by gallic acid may be
responsible for its antidiabetic action [48]. Moreover, the
contentofquercetininEESIRwashigherthangallicacid,and
hence this data supports that quercetin may be responsible
for the antidiabetic, antihyperlipidemic, and antioxidant
activity. The gallic acid may act adjuvant with quercetin that
probably results in better pharmacological action of EESIR.
The hypothetical pharmacological action of S. indicus root is
represented in the schematic diagram (Figure 9).
5. Conclusion
The present ﬁndings clearly demonstrated that the roots of
Sphaeranthus indicus exhibited antidiabetic, hypolipidemic,
and in vivo antioxidant eﬀects in STZ-induced diabetes.
These activities may possibly due to presence of biomarker
compounds such as gallic acid and quercetin in this plant
root which indirectly helped to decrease the levels of glucose,
prevent the alteration of lipids level and increase antioxidant
status in diabetic condition.
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